First-in-human experience of a new-generation transfemoral transcatheter aortic valve for the treatment of severe aortic regurgitation: the J-Valve transfemoral system

EuroIntervention Journal

Transcatheter aortic valve implantation (TAVI) is now well established in the contemporary management of severe aortic stenosis (AS) with a multitude of valve designs available. The transapical (TA) J-Valve™ system (JC Medical Inc., Burlingame, CA, USA) has previously been shown to be effective for the treatment of both severe AS and aortic regurgitation (AR).

The J-Valve transcatheter aortic valve consists of the valve and three U-shaped “anchor rings” and is deployed in a two-step process. The transfemoral (TF) valve is delivered by an 18 Fr steerable delivery system. First, the anchor rings are opened above the native valve and are retracted (TA) or advanced (TF) into the valve apparatus allowing automatic anatomic alignment in the aortic sinuses and clasping of the native valve leaflets. This can be visualised on fluoroscopy. Once positioned, the self-expanding valve is then deployed within the anchor rings and secures the native valve leaflets. The valve, which is not recapturable, is currently available in three sizes. We present the first-in-human experience of the TF J-Valve system for the treatment of severe AR.

Read full article